[go: up one dir, main page]

MX2012007536A - Derivados de heteroarilo que contienen nitrogeno. - Google Patents

Derivados de heteroarilo que contienen nitrogeno.

Info

Publication number
MX2012007536A
MX2012007536A MX2012007536A MX2012007536A MX2012007536A MX 2012007536 A MX2012007536 A MX 2012007536A MX 2012007536 A MX2012007536 A MX 2012007536A MX 2012007536 A MX2012007536 A MX 2012007536A MX 2012007536 A MX2012007536 A MX 2012007536A
Authority
MX
Mexico
Prior art keywords
nitrogen
containing heteroaryl
heteroaryl derivatives
derivatives
medicaments
Prior art date
Application number
MX2012007536A
Other languages
English (en)
Inventor
Bernd Kuhn
Eric Vieira
Jens-Uwe Peters
Konrad Bleicher
Alexander Flohr
Rosa Maria Rodriguez Sarmiento
Matthias Koerner
Katrin Groebke Zbinden
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012007536A publication Critical patent/MX2012007536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a los derivados de heteroarilo que contienen nitrógeno nuevos de la fórmula (I) en donde R1, R2, R3, R4, R5, A1, A2, y Y son como se definió en la descripción y en las reivindicaciones, así como sales y esteres fisiológicamente aceptables de los mismos. Estos compuestos inhiben PDE10A y pueden ser utilizados como medicamentos.
MX2012007536A 2010-01-22 2011-01-19 Derivados de heteroarilo que contienen nitrogeno. MX2012007536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151364 2010-01-22
PCT/EP2011/050640 WO2011089132A1 (en) 2010-01-22 2011-01-19 Nitrogen-containing heteroaryl derivatives

Publications (1)

Publication Number Publication Date
MX2012007536A true MX2012007536A (es) 2012-07-30

Family

ID=43856012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007536A MX2012007536A (es) 2010-01-22 2011-01-19 Derivados de heteroarilo que contienen nitrogeno.

Country Status (10)

Country Link
US (1) US8470820B2 (es)
EP (1) EP2526098B1 (es)
JP (1) JP5735987B2 (es)
KR (1) KR101734606B1 (es)
CN (1) CN102712625B (es)
BR (1) BR112012017580A2 (es)
CA (1) CA2782588A1 (es)
MX (1) MX2012007536A (es)
RU (1) RU2559895C2 (es)
WO (1) WO2011089132A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130405A1 (es) 2010-04-07 2013-04-10 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
US8703768B2 (en) * 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
ME02419B (me) * 2011-08-25 2016-09-20 Merck Sharp & Dohme Inhibitori pirimidina pde10
US8614206B2 (en) 2011-09-27 2013-12-24 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2975037A4 (en) * 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN106488909A (zh) * 2014-07-31 2017-03-08 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
JP2018505168A (ja) * 2015-01-30 2018-02-22 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性フェニルピリミジン
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
AU2018355002B2 (en) * 2017-10-26 2024-03-14 Delaval Holding Ab A connector for a teatcup to be attached to the teat of an animal to be milked, and a teatcup
BR112020013697A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
KR20250127326A (ko) * 2022-12-31 2025-08-26 난징 이뮤노파지 바이오테크 코., 엘티디. 대식세포 이동 저해 인자의 저해제로서의 화합물 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0008489A (pt) * 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2007524682A (ja) 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
MX2007003377A (es) * 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
ES2476840T3 (es) 2005-03-04 2014-07-15 F. Hoffmann-La Roche Ag Derivados de piridina-2-carboxamida como antagonistas de MGLUR5
EP1945644A2 (en) 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines as protein kinase inhibitors
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
WO2010077992A1 (en) * 2008-12-17 2010-07-08 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
CN102548991B (zh) * 2009-09-24 2015-03-25 霍夫曼-拉罗奇有限公司 作为磷酸二酯酶10a抑制剂的咪唑并吡啶或咪唑并嘧啶衍生物

Also Published As

Publication number Publication date
US20110183979A1 (en) 2011-07-28
KR101734606B1 (ko) 2017-05-11
CN102712625A (zh) 2012-10-03
CA2782588A1 (en) 2011-07-28
WO2011089132A1 (en) 2011-07-28
HK1171744A1 (en) 2013-04-05
US8470820B2 (en) 2013-06-25
EP2526098A1 (en) 2012-11-28
RU2012134306A (ru) 2014-02-27
BR112012017580A2 (pt) 2016-08-16
JP5735987B2 (ja) 2015-06-17
RU2559895C2 (ru) 2015-08-20
JP2013517316A (ja) 2013-05-16
EP2526098B1 (en) 2018-07-11
CN102712625B (zh) 2014-04-09
KR20120124454A (ko) 2012-11-13

Similar Documents

Publication Publication Date Title
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
PH12012502335A1 (en) Nitrogen containing heteroaryl compounds
PH12012501772A1 (en) N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors
PH12013500942A1 (en) Triazolopyridine compounds
PH12012500355A1 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
NZ704147A (en) Partially saturated nitrogen-containing heterocyclic compound
TW200833324A (en) Sulfonamide derivatives
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
PH12016500250B1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
MX2009010218A (es) Derivados de aza-piridopirimidinona.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
IN2012DN03337A (es)
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
MX340607B (es) Moduladores de la fosfodiesterasa 10 (pde 10).
MX2015011534A (es) Nuevos derivados de pirazol.
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
MX349373B (es) Nuevos derivados de pirazina.
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
IN2012DN01232A (es)

Legal Events

Date Code Title Description
FG Grant or registration